BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 12601150)

  • 21. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.
    Gorbatyuk OS; Li S; Sullivan LF; Chen W; Kondrikova G; Manfredsson FP; Mandel RJ; Muzyczka N
    Proc Natl Acad Sci U S A; 2008 Jan; 105(2):763-8. PubMed ID: 18178617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.
    Koprich JB; Johnston TH; Huot P; Reyes MG; Espinosa M; Brotchie JM
    PLoS One; 2011 Mar; 6(3):e17698. PubMed ID: 21408191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
    Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
    Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.
    Moloney TC; Hyland R; O'Toole D; Paucard A; Kirik D; O'Doherty A; Gorman AM; Dowd E
    CNS Neurosci Ther; 2014 Jan; 20(1):50-8. PubMed ID: 24279716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra.
    Klein RL; King MA; Hamby ME; Meyer EM
    Hum Gene Ther; 2002 Mar; 13(5):605-12. PubMed ID: 11916484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Drosophila model of Parkinson's disease.
    Feany MB; Bender WW
    Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.
    Gombash SE; Manfredsson FP; Kemp CJ; Kuhn NC; Fleming SM; Egan AE; Grant LM; Ciucci MR; MacKeigan JP; Sortwell CE
    PLoS One; 2013; 8(11):e81426. PubMed ID: 24312298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
    Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
    Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
    J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors.
    Van der Perren A; Toelen J; Casteels C; Macchi F; Van Rompuy AS; Sarre S; Casadei N; Nuber S; Himmelreich U; Osorio Garcia MI; Michotte Y; D'Hooge R; Bormans G; Van Laere K; Gijsbers R; Van den Haute C; Debyser Z; Baekelandt V
    Neurobiol Aging; 2015 Mar; 36(3):1543-58. PubMed ID: 25599874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
    Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
    Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
    Chu Y; Kordower JH
    Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
    Arawaka S; Fukushima S; Sato H; Sasaki A; Koga K; Koyama S; Kato T
    PLoS One; 2014; 9(2):e89076. PubMed ID: 24586512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice.
    Alerte TN; Akinfolarin AA; Friedrich EE; Mader SA; Hong CS; Perez RG
    Neurosci Lett; 2008 Apr; 435(1):24-9. PubMed ID: 18314273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
    Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
    Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
    Eslamboli A; Romero-Ramos M; Burger C; Bjorklund T; Muzyczka N; Mandel RJ; Baker H; Ridley RM; Kirik D
    Brain; 2007 Mar; 130(Pt 3):799-815. PubMed ID: 17303591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.
    Masliah E; Rockenstein E; Veinbergs I; Mallory M; Hashimoto M; Takeda A; Sagara Y; Sisk A; Mucke L
    Science; 2000 Feb; 287(5456):1265-9. PubMed ID: 10678833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
    Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
    Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.
    Gründemann J; Schlaudraff F; Haeckel O; Liss B
    Nucleic Acids Res; 2008 Apr; 36(7):e38. PubMed ID: 18332041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
    St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
    J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.